Education and Training
Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study
The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein profile.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Pine Bark Extract (Flavangenol®)
Eligibility
Inclusion Criteria:
- Systolic blood pressure between 125 and 159 mmHg and diastolic blood pressure (DBP) <
100 mmHg
- Body mass index (BMI) 25.0-34.9
- Triglycerides (TG) < 450 mg/dL
- Low Density Lipoprotein (LDL) < 200 mg/dL
- Fasting blood glucose (FBG) < 126 mg/dL
Exclusion Criteria:
- DBP > 95 mmHg
- LDL > 170 mg/dL
- TG > 300 mg/dL
- FBG > 110 mg/dL
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Rebbeca Drieling
6507236528
Not Recruiting